Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings or view top-rated stocks.

8 brokerages have issued 12 month price objectives for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they predict the company's share price to reach $22.71 in the next year. This suggests a possible upside of 78.6% from the stock's current price.
View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts.

Deciphera Pharmaceuticals' stock was trading at $16.39 at the start of the year. Since then, DCPH shares have decreased by 22.4% and is now trading at $12.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DCPH earnings forecast.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its earnings results on Wednesday, August, 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.05. The company earned $38.30 million during the quarter, compared to the consensus estimate of $36.09 million. Deciphera Pharmaceuticals had a negative net margin of 129.90% and a negative trailing twelve-month return on equity of 47.99%. The business's revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.60) EPS.

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).Range Cancer Therapeutics ETF (CNCR).

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $12.72.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.00 billion and generates $134.04 million in revenue each year. The company earns $-178,930,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

The company employs 300 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.